About Celsius Therapeutics
Celsius Therapeutics is a company based in Cambridge (United States) founded in 2018 was acquired by AbbVie in June 2024. Celsius Therapeutics has raised $148 million across 2 funding rounds from investors including Amgen, AbbVie and ARE. The company has 50 employees as of December 31, 2022. Celsius Therapeutics operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter Cambridge, United States
- Employees 50 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Celsius Therapeutics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Celsius Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
326 people
Software Development Team
295 people
Sales and Marketing
173 people
Senior Team
76 people
Product Management Team
75 people
Human Resources and Administration
63 people
Operations Team
56 people
Data Analysis and Operations Team
47 people
Unlock access to complete
Funding Insights of Celsius Therapeutics
Celsius Therapeutics has successfully raised a total of $148M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $83 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Celsius Therapeutics
Celsius Therapeutics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, AbbVie and ARE.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment and consultation services in healthcare and life sciences are delivered by the company.
|
Locked | Locked | Locked | |
|
VC fund investing in startups
|
Locked | Locked | Locked | |
|
Venture capital is provided to biomedical technology startups.
|
Locked | Locked | Locked |
Investor details for Celsius Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Celsius Therapeutics
Investment portfolio details for Celsius Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Celsius Therapeutics
Detailed financials for Celsius Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Celsius Therapeutics Comparisons
Peer comparison for Celsius Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Celsius Therapeutics
Celsius Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| Locked | Locked | Locked |
Diagnostic services are provided through laboratories and radiology units.
|
Detailed competitors of Celsius Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Celsius Therapeutics
Complete news archive for Celsius Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Celsius Therapeutics
Celsius Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Celsius Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Celsius Therapeutics is a funded company, having raised a total of $148M across 2 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Celsius Therapeutics is 50.
Celsius Therapeutics was founded in 2018 and is based in Cambridge, United States. Operations center on the biotechnology sector, where single-cell genomic sequencing is integrated with computational algorithms. This approach is used to identify therapies targeting autoimmune diseases and cancer. Services encompass RNA analysis and genomic data processing to support precision medicine development.
Celsius Therapeutics's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
Celsius Therapeutics has 13 investors. Key investors include Amgen, AbbVie, ARE, Fast Track Initiative, and Co-win Ventures.